182 results about "Gut barrier" patented technology

The invention relates to health uses of a composition comprising Bifidobacterium animalis subsp. lactis strain CECT 8145, in the form of viable and non-viable cells. and / or a lipoteichoic acid (LT A) thereof, more particularly, for its use in anxiety, pathogen protection, gut barrier or age-related conditions in a subject. Given the associated effects, the invention is thus useful for exploitation in pharmaceutical and veterinary areas, food and beverages developments, animal feed, or medical foods among others.

The invention discloses kluyveromyces marxianus KUST3801 for preventing and treating celiac disease, application of the kluyveromyces marxianus KUST3801 and a fruit and vegetable fermented beverage. The preservation number is CGMCC NO. 32767; the Kluyveromyces marxianus strain is classified and named as Kluyveromyces marxianus, and the Kluyveromyces marxianus strain is named as Kluyveromyces marxianus. The strain can be used for effectively preventing and treating celiac disease by protecting intestinal mucosa and intestinal barrier, regulating immunity and relieving inflammation. In addition, in the preparation of the fermented fruit and vegetable juice beverage, the aroma of the beverage can be improved, and the antioxidant activity is enhanced.

The invention discloses a construction method and application of a caenorhabditis elegans inflammation model, belongs to the technical field of model biology, and provides a construction method of a caenorhabditis elegans inflammation model, which comprises the following steps: putting L1-stage caenorhabditis elegans into a lipopolysaccharide solution, and carrying out induced culture to obtain induced cultured caenorhabditis elegans; placing the caenorhabditis elegans in a chromosome system, performing staining culture and centrifugation to obtain dyed caenorhabditis elegans, and placing the dyed caenorhabditis elegans on a culture medium for recovery to obtain the caenorhabditis The surface of the caenorhabditis elegans is provided with a transparent cuticle anatomical structure, the intestinal barrier damage condition is easy to observe after the intestinal tract is dyed by a dye, and the cell proliferation, tissue development and tissue integrity of the caenorhabditis elegans are easy to carry out fluorescence microscope and morphological analysis. A caenorhabditis elegans inflammation model is constructed through lipopolysaccharide induction, and a new experimental animal model is provided for screening anti-inflammatory drugs.

The invention relates to a montmorillonite-probiotic microsphere preparation as well as a preparation method and application thereof, the microsphere preparation comprises montmorillonite, a probiotic biofilm and functional small molecules, and microspheres of the microsphere preparation are prepared by crosslinking sodium alginate in a collection solution based on a microfluidic technology. The microsphere preparation is mainly used for oral delivery of montmorillonite-probiotic biofilms and functional small molecules, so as to treat intestinal diseases. Compared with the prior art, the microsphere preparation provided by the invention has the advantages of gastric acid invasion resistance, intestinal responsive release and the like, and can effectively treat intestinal inflammation. In addition, the probiotic biofilm wrapped by the microspheres can enhance the interaction with the intestinal mucosa and prolong the residence time in the intestinal tract. Meanwhile, the used functional small molecules have excellent anti-inflammatory and intestinal barrier repairing effects, and can cooperate with the probiotics to regulate and control intestinal flora, so that the intestinal health is further improved.

The invention belongs to the technical field of probiotic products, and particularly relates to lactobacillus rhamnosus JM039 as well as a composition and application thereof. The preservation number of the lactobacillus rhamnosus JM039 is GDMCC No: 64409. The lactobacillus rhamnosus JM039 is a lactobacillus rhamnosus strain. The composition is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum JY039 and lactobacillus rhamnosus JM039, and is prepared from lactobacillus reuteri J1, lactobacillus gasseri JM1, lactobacillus paracasei JY062, lactobacillus paracasei with the preservation number of GDMCC.No.62990, lactobacillus plantarum The combined bacteria of the six probiotics can improve the levels of anti-inflammatory factors and intestinal epithelium tight junction proteins and reduce the levels of proinflammatory factors and claudin-2 mRNA, so that the intestinal microenvironment homeostasis and intestinal barrier integrity are maintained through double regulation of inflammatory factors and tight junction proteins, and necrotizing enterocolitis can be relieved.

The invention discloses multi-component inulin hydrogel as well as a preparation method and application thereof, and belongs to the technical field of nano materials and medicines.The multi-component inulin hydrogel is characterized in that a medicine L-alanyl-L-glutamine contributing to intestinal mucosa repair is entrapped in the inulin hydrogel; the multi-component inulin hydrogel has the advantages that the multi-component inulin hydrogel is prepared from the inulin and composite nanoparticles (namely mesoporous polydopamine-gallium composite nanoparticles) composed of an active oxygen scavenger polydopamine and an antibacterial agent gallium ions, the repairing capacity on intestinal barriers is further enhanced, and the prepared multi-component inulin hydrogel can be used for effectively treating inflammatory bowel diseases and non-alcoholic steatohepatitis.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

The invention discloses an application of intestinal bacteria in an ulcerative colitis prediction technology, and belongs to the technical field of biology, and the intestinal bacteria are Alistipes finegoldii; the method comprises the following steps: detecting the relative abundance of Alistipes finegii in an excrement sample of a patient, and using the low relative abundance of Alistipes finegii to predict the disease activity of ulcerative colitis; according to the application disclosed by the invention, not only is the association between the Alistipes finegili and the UC disease activity verified, but also the potential action mechanism of the Alistipes finegili is further explored. By means of 16s amplicon sequencing and transcriptomics combined analysis, it is found that the Alistipes finegili plays an anti-inflammatory role through an Hsp90 / AMPK / ACC signal channel, and the intestinal barrier function is maintained. The invention verifies that a new view angle is provided for the effect of the Alistipes finegili in the UC pathogenesis, and provides a theoretical basis for developing a treatment strategy based on the strain.

The invention provides an application of lactobacillus rhamnosus NKU FL1-8 in resisting obesity, serum inflammation and cognitive impairment caused by high fat diet, and belongs to the technical field of microorganisms. The lactobacillus rhamnosus NKU FL1-8 has the advantages that the lactobacillus rhamnosus NKU FL1-8 can be used for resisting the obesity, the serum inflammation and the cognitive impairment caused by high fat diet; the invention finds that the lactobacillus rhamnosus NKU FL1-8 can obviously reduce adipose tissue increase caused by high-fat diet, relieve liver function impairment caused by high-fat diet, inhibit serum inflammation caused by high-fat diet, improve cognitive impairment caused by high-fat diet, strengthen intestinal barrier, increase the content of short-chain fatty acid in cecum and excrement and improve the immunity of the cecum. The intestinal flora is regulated, and the diversity of the intestinal flora is improved, so that related diseases caused by high-fat diet are effectively resisted.

The invention belongs to the field of food nutrition and functional factors, and particularly relates to a method for preparing ovotransferrin hydrolysate with high immunocompetence based on an adult gastrointestinal simulated digestion system. According to the method, ovotransferrin is treated through the stomach and intestine of a simulated adult, OVT hydrolysate is prepared, and the OVT hydrolysate contains HTEGSTT, TTSY and / or RTAGWVIPMG. The invention finds that the immunomodulatory activity of OVT is enhanced after gastrointestinal digestion and hydrolysis, the OVT is more easily hydrolyzed in simulated adult digestive juice than in infant digestive juice, and a contrast experiment shows that the nutrition intervention of OVT adult and infant simulated digestion products can promote the generation of short-chain fatty acids such as acetic acid, propionic acid and butyric acid; the swelling injury caused by inflammation to small intestine mucous membrane tissues is effectively relieved, so that the intestinal barrier immune function is obviously improved, and the OIA shows higher intestinal immune activity than the OIB.

The invention discloses an application of Ackermann muciniphile and an outer membrane protein Amuc1100 of Ackermann muciniphile in treatment of hypertension. The outer membrane protein Amuc1100 is a protein of which the amino acid sequence is as shown in SEQ ID NO: 4. Experiments prove that the outer membrane protein Amuc1100 can enhance the intestinal barrier function of a mouse, blood pressure is reduced by remodeling the cardiovascular system and improving the intestinal microenvironment, and the blood pressure comprises systolic pressure and diastolic pressure. The invention has important application value in prevention and / or treatment of hypertension.

According to the present invention, a method for producing a hot water extract of an aboveground portion of a plant of the genus aralia is characterized by comprising a step for adding sodium hydrogen carbonate.

The present invention relates to a composition comprising human milk oligosaccharides and probiotics and an application thereof for improving intestinal development. The human milk oligosaccharides are neutral fucosylated human milk oligosaccharides, and the probiotics are animal bifidobacteria. The composition can synergistically improve the development of the glycocalyx layer of intestinal epithelial cells, prevent the adhesion of pathogens through the good development of the glycocalyx layer of intestinal epithelial cells, provide good binding sites for symbiotic microorganisms, and further promote the development of intestinal barrier function and intestinal development.

The invention discloses a curcumin nanocrystal preparation as well as a preparation method and application thereof. The invention relates to a curcumin nanocrystal composition which is prepared by drying and curing a curcumin nanocrystal suspension to a blank pellet core, the curcumin nanocrystal suspension contains 20-35% of curcumin nanocrystals, 1-10% of a three-dimensional protective agent and 1-10% of a charge protective agent, and the average particle size of the curcumin nanocrystals is 200-320 nm. The curcumin nanocrystal composition prepared by the invention can effectively prevent and treat heat stroke and complications thereof, remarkably improve heat tolerance, prolong survival time, reduce the level of inflammatory factors in blood, protect intestinal epithelial cells and intestinal barrier functions, reduce damage caused by heat stroke, prevent and treat body and organ damage caused by heat stroke, and improve the curative effect of the curcumin nanocrystal composition. The preparation has the advantages of being high in drug loading capacity, good in stability, high in bioavailability, safe, effective, convenient to carry and the like.

Orally administered compositions comprising triacetin are presented that increase the concentration of short chain fatty acids in the gut, namely acetic acid, wherein the compositions comprising triacetin are palatable at desirable concentrations. The triacetin formulations can also be orally administered to a dysbiotic subject to increase short chain fatty acid (SCFA) concentrations in the gut of the subject while substantially avoiding gas production in the subject. Advantageously, administration of contemplated compositions also increases gut barrier integrity and helps restore a balanced gut microbiome.

The invention relates to a nutritional composition for infants, for children as well as a medical nutritional composition, comprising human milk oligosaccharides and Bifidobacterium breve. The invention further relates to the use of said nutritional composition for strengthening the gut epithelial defense and / or the gut barrier function.

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and / or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

The invention relates to a solid beverage for maintaining intestinal-brain axes as well as a preparation method and application of the solid beverage, and belongs to the technical field of food processing. The health-care tea powder consists of cold-extracted freeze-dried tea powder, theanine powder, fructus phyllanthi powder, PQQ powder or microencapsulated PQQ powder, targeted probiotic microcapsule powder, mogroside and galactooligosaccharide. During preparation, the cold-extracted freeze-dried tea powder, the microencapsulated PQQ powder and the purchased targeted probiotic microcapsule powder are respectively prepared and then are mixed with other raw materials. The innovation of the invention lies in that the intestine-brain axis is synergistically maintained through a four-dimensional mechanism of anti-inflammatory and anti-oxidation-neuromodulation-mitochondrial activation-flora intervention, and the activity of the components is guaranteed by adopting technologies of cold extraction freeze-drying, microencapsulation and the like. The system can inhibit enteropathogenic bacteria, repair intestinal barriers, protect nervous systems, improve cognitive functions and regulate intestinal flora, has high technical feasibility and market prospects, and makes remarkable progress compared with the prior art.

The present invention relates to the field of medical detection technology, and discloses a method for evaluating the severity of intestinal barrier damage based on blood and fecal ferritin detection, including the preparation of ferritin content detection in blood and feces and ferritin as a marker that can be independently applied to intestinal barrier damage assessment and prediction of high-risk populations. The present invention provides a specific basis for risk prediction, prognosis and disease progression monitoring of patients with intestinal barrier damage, greatly advances the timing of clinical diagnosis and treatment decisions, fills the gap in medical industry research and clinical application, and has great potential and value for clinical and market applications.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

This invention belongs to the field of anti-aging functional food technology, specifically relating to an anti-aging and longevity composition containing inactivated Akkermansia myxophilus. Existing anti-aging products are mostly single-ingredient products. The composition of this invention contains inactivated Akkermansia myxophilus, NMN, coenzyme Q10, resveratrol, and astaxanthin. This invention achieves the effects of delaying aging, improving muscle strength, and enhancing cognitive function by repairing the intestinal barrier, increasing NAD+ levels, and activating longevity pathways. The composition of this invention is stable at room temperature and can be formulated into capsules or powder.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

The application relates to the technical field of organ chip, and discloses a biocompatible membrane sheet, which comprises wave structures continuously distributed in one direction, and the wave structures are in a hollow structure. The biocompatible membrane sheet disclosed by the application has consistent hollow wrinkle forms, uniform deformation when the biocompatible membrane sheet is subjected to external force, better transmission and fluctuation, and can more truly reproduce the dynamic change state of an organ in vitro. The application further discloses an organ chip, an intestinal organ chip, an intestinal organ chip system, a membrane sheet preparation method, an intestinal organ chip preparation method and an intestinal barrier construction method.

This invention discloses Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. It belongs to the field of microbial shell-core gel technology, and particularly relates to Bifidobacterium microspheres for alleviating Salmonella typhimurium infection. The Bifidobacterium microspheres are prepared by mixing a thermal copolymer with Bifidobacterium, then adding it dropwise to a calcium chloride aqueous solution for the first cross-linking, followed by immersion in a tannic acid aqueous solution for the second cross-linking. The thermal copolymer is obtained by mixing equal volumes of polysaccharide aqueous solution and protein aqueous solution. This invention provides Bifidobacterium microspheres for alleviating Salmonella typhimurium infection, their preparation method, and applications. The Bifidobacterium microspheres prepared by this invention achieve concentrated responsive release of Bifidobacterium in the cecum, improving intestinal retention and adhesion colonization efficiency. Their alleviating effect on Salmonella typhimurium infection exceeds that of free bacteria, exhibiting better intestinal barrier damage repair and flora regulation effects.

The invention belongs to the technical field of medicine and pharmacy, and particularly relates to application of an AP1B1 allosteric activator of ethyl gallate. In the invention, AP1B1 is a beta 1 subunit (AP1B1) of a linking factor associated protein complex 1 (AP-1), and is an essential component for assembling a functional AP-1B complex. The ethyl gallate is used as an allosteric activator of AP1B1 and is specifically combined with an allosteric pocket of the AP1B1 to induce the AP1B1 to generate conformational change, so that the vesicle transportation function of an AP1B complex is activated, and the substrate-side membrane protein sorting capacity is recovered. A target dependence experiment verifies that the effect of ethyl gallate on promoting tight junction protein ZO-1 expression and membrane localization in AP1B1 knocked-down Caco-2 cells is remarkably weakened, and it is prompted that the intestinal barrier protection function of ethyl gallate depends on AP1B1. The invention provides a new strategy for developing medicines for treating intestinal barrier injury related diseases.

The invention discloses an application of an lncRNA-MALAT1 / miR-145 / BNIP3 regulation axis in preparation of a medicine for treating hemorrhagic shock ischemia reperfusion intestinal injury. In existing treatment, conventional liquid resuscitation easily causes serious inflammation and pathological apoptosis, the intestinal barrier repair effect is limited, and the molecular mechanism is not completely clarified. The invention discloses that a regulatory axis participates in an intestinal injury process through a ceRNA mechanism (MALAT1 is used as miR-145 sponge to inhibit regulation of BNIP3 and mediate controlled programmed cell death instead of pathological apoptosis), and provides a new molecular target for treatment. The medicine aiming at the regulation shaft can relieve inflammatory response, reduce pathological apoptosis and promote intestinal barrier repair, and has a good application prospect.

The invention provides application of P.distassonis ATCC: 8503 in treatment of intestinal ischemia reperfusion injury, and belongs to the technical field of microorganisms. According to the application disclosed by the invention, the P.distaxis ATCC: 8503 is used for treating the intestinal ischemia-reperfusion injury, the treatment effect of the P.distaxis ATCC: 8503 is detected, and a result proves that the P.distaxis ATCC: 8503 can be used for inhibiting the pathological morphology injury of intestinal tissues induced by the intestinal ischemia-reperfusion injury, reducing the content of FITC (Fluorescein Isothiocyanate) and LPS (Lipopolysaccharide) in serum and reducing the permeability of an intestinal barrier, so that the P.distaxis ATCC: 8503 can be used for treating the intestinal ischemia-reperfusion injury. The intestinal barrier function injury induced by the intestinal ischemia reperfusion injury is relieved, and the endotoxin displacement and the kidney injury induced by the intestinal ischemia reperfusion injury of the mouse are relieved.

The invention discloses application of anthocyanin based on intestinal flora-intestinal barrier regulation in prevention and treatment of gestational diabetes mellitus, and relates to the technical field of biological medicines, and the technical key points are as follows: the anthocyanin Cy-3-G can improve the intestinal barrier function and reduce inflammatory response by regulating intestinal flora, and can be used for preventing and treating gestational diabetes mellitus. Glucose homeostasis and insulin resistance of HFD mice can be effectively improved, complications of gestational diabetes mellitus are reduced, and health of mothers and infants is guaranteed.